预约演示
更新于：2025-04-17
Brimonidine Tartrate
酒石酸溴莫尼定
更新于：2025-04-17
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C15H16BrN5O6 |
InChIKeyQZHBYNSSDLTCRG-LREBCSMRSA-N |
CAS号70359-46-5 |
关联
137
项与 酒石酸溴莫尼定 相关的临床试验NCT04007276
The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1%
ChiCTR2500100068
A Randomized, Double-Blind, Placebo-Controlled, Self-Controlled Study on the Analgesic-Enhancing Effect of Brimonidine Tartrate Eye Drops as an Adjunct to Compound Lidocaine Cream - The use of brimonidine tartrate ophthalmic solution as an adjuvant to enhance the analgesic effect of compound lidocaine cream in patients undergoing photoelectric therapy
NCT06818058
A Phase II Multicentric, Randomized, Double-blind, Placebo-controlled Study of TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis.
100 项与 酒石酸溴莫尼定 相关的临床结果
登录后查看更多信息
100 项与 酒石酸溴莫尼定 相关的转化医学
登录后查看更多信息
100 项与 酒石酸溴莫尼定 相关的专利（医药）
登录后查看更多信息
2,821
项与 酒石酸溴莫尼定 相关的文献（医药）2025-06-01EXPERIMENTAL EYE RESEARCH
Effect of brimonidine on retinal ganglion cell function by in vivo calcium imaging of optic nerve crush in mice
Article
作者: Li, Tingting ; Sun, Yang ; Zhao, Jingyu ; Ning, Ke ; Jin, Haiying ; Li, Liang ; Liu, Zhiquan ; Shen, Yingchun ; Yu, Jing ; Wang, Qing ; Lo, Chien-Hui ; Kowal, Tia J
Brimonidine has shown neuroprotective effects in animal studies, but clinical trials failed to demonstrate effective endpoints. Here, we used a newly developed in vivo calcium imaging method to measure RGC function of brimonidine in mice optic nerve crush (ONC) models. To transduce RGCs in vivo, wild-type C57Bl/6j mice were treated with intravitreal AAV2-mSncg-jGCaMP7s, a live-cell Ca2+ tracer. RGCs are defined as 10 subtypes according to different responses to UV light. Mice were treated with topical brimonidine or placebo three times daily for two weeks after ONC. The calcium signals of live-cell RGCs were measured with the Heidelberg cSLO system. Ganglion cell complex (GCC) thickness and IOP were examined at different timepoints after treatment. RGCs were counted after RBPMS immunostaining. Live calcium imaging showed ONC significantly decreased RGC number at 14 days post-ONC compared to controls. The topical brimonidine administration changed calcium signal responses of RGC to UV light in ONC mice. It showed brimonidine partly prevented the decrease of survival ON-RGCs percent after ONC. Single RGC analysis showed a lower conversion percent of ON-RGCs to OFF-RGCs with brimonidine administration after ONC. However, no significant differences in RGC survival, IOP or GCC thickness were noted between eyes treated with brimonidine or placebo. In the acute ONC mice model, in vivo calcium imaging revealed that brimonidine maintained the Ca2+ activation of ON-RGCs to UV stimulation, inhibiting the conversion of survival ON-RGCs to OFF-RGCs. This indicates that ON-RGCs may be more resilient to acute optic nerve injury based on the calcium imaging method.
2025-05-01Veterinary Medicine and Science
Central Nervous System Depression After Topical Administration of Brimonidine Eye Drops to Induce Vomiting in a Cat
Article
作者: Jung, Joohyun ; Kim, Dalhae ; Park, Eunbin ; Son, Won‐gyun ; Jun, Jaehan
ABSTRACT:
Brimonidine stimulates the chemoreceptor trigger zone via alpha‐2 adrenergic receptors in the postrema of the medulla, which triggers vomiting in cats. This case report details the occurrence of central nervous system (CNS) depression following brimonidine administration to induce vomiting in a cat that had ingested a toxic substance. A 12‐year‐old neutered male American Shorthair cat was presented to the hospital after ingesting two leaves of Anthurium polyschistum, which is toxic to cats. 0.15% of brimonidine eye drops intended for ocular administration were accidentally administered onto the upper eyelids, resulting in the administration of four drops in total. Three incidents of projectile vomiting were then observed 30 min after the brimonidine administration. The cat began to show signs of CNS depression, including deep sedation and respiratory depression after vomiting. Brimonidine use was the suspected aetiology of the CNS depression. Atipamezole (200 µg/kg) was administered intramuscularly; after 5 min, the clinical signs of the CNS depression resolved. This case suggests that while brimonidine may serve as an effective emetic agent in feline patients, its systemic effects, particularly CNS depression, warrant careful monitoring. The potential impact of higher concentrations and increased dosing volume remains uncertain, highlighting the need for further research to establish safe and standardized dosing guidelines.
2025-03-01MACROMOLECULAR RAPID COMMUNICATIONS
Bis‐Naphthylacrylonitrile‐Based Supramolecular Artificial Light‐Harvesting System for White Light Emission
Article
作者: Wu, Lujie ; Fu, Yuan ; Wang, Ruixin ; Zhu, Jinli ; Sun, Guangping ; Tang, Yanfeng ; Xia, Yang ; Li, Menghang ; Yao, Yong
Abstract:
A novel aggregation‐induced emission (AIE)‐based artificial light‐harvesting system (LHS) is successfully assembled via the host‐guest interaction of bis‐naphthylacrylonitrile derivative (BND), water‐soluble pillar[5]arene (WP5), and sulforhodamine 101 (SR101). After host‐guest assembly, the formed WP5⊃BND complexes spontaneously self‐aggregated into WP5⊃BND nanoparticles (donors) and SR101 (acceptors) is introduced into WP5⊃BND to fabricate WP5⊃BND‐SR101 LHS. Through the investigation of energy transfer between donors and acceptors, the artificial light‐harvesting processes are certified in WP5⊃BND‐SR101 LHS and the absolute fluorescence quantum yields (Φf(abs)) are significantly improved from 8.9% (for WP5⊃BND) to 31.1% (for WP5⊃BND‐SR101), exhibiting the excellent light‐harvesting capabilities. Notably, by tuning the donor/acceptor (D:A) molar ratio to 250:1, a conspicuous white light emission (CIE coordinate is (0.32, 0.32)) is realized and the fluorescence quantum yield of white light emission (Φf(abs)WP5⊃BND‐SR101‐White) is 29.2%. Moreover, the antenna effect of white fluorescence emission (AEWP5⊃BND‐SR101‐White) can reach 36.2, which is higher than that of recent artificial LHSs in water environments, suggesting vast potential applications in aqueous LHSs.
100 项与 酒石酸溴莫尼定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼睛发红 | 美国 | 2017-12-22 | |
| 玫瑰痤疮 | 美国 | 2013-08-23 | |
| 青光眼 | 日本 | 2012-01-18 | |
| 低眼压 | 美国 | 2005-08-19 | |
| 开角型青光眼 | 美国 | 1996-09-06 | |
| 高眼压症 | 美国 | 1996-09-06 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 季节性过敏性结膜炎 | 临床3期 | 美国 | 2022-11-18 | |
| 变应性结膜炎 | 临床3期 | 美国 | 2022-10-12 | |
| 先天性毛细血管畸形1 | 临床3期 | 加拿大 | - | 2016-06-01 |
| 红斑 | 临床3期 | 美国 | 2013-11-07 | |
| 充血 | 临床3期 | 美国 | 2013-11-07 | |
| 皮疹 | 临床2期 | 法国 | 2025-01-20 | |
| 毛囊炎 | 临床2期 | 法国 | 2025-01-20 | |
| 视网膜脱离 | 临床2期 | 美国 | 2009-11-01 | |
| 视网膜脱离 | 临床2期 | 印度 | 2009-11-01 | |
| 视网膜脱离 | 临床2期 | 以色列 | 2009-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 188 | Brimonidine tartrate 0.025%/ketotifen fumarate 0.035% (Combination) | 範顧繭衊顧廠獵壓獵齋(獵壓廠窪觸觸繭簾窪鹽) = 糧糧積範鹹鹽觸鹹壓範 觸網築壓鹹網鏇廠蓋糧 (選獵鹹鏇獵鹹襯膚膚範, 0.1464) 更多 | - | 2025-02-14 | ||
(Ketotifen Fumarate) | 範顧繭衊顧廠獵壓獵齋(獵壓廠窪觸觸繭簾窪鹽) = 願夢簾襯窪壓獵鹽糧鹽 觸網築壓鹹網鏇廠蓋糧 (選獵鹹鏇獵鹹襯膚膚範, 0.1487) 更多 | ||||||
临床3期 | 380 | (Brimonidine Tartrate Preservation-free) | 窪築鬱壓醖選繭壓鹹醖(壓鏇壓繭構選範觸壓壓) = 獵築鬱淵齋製蓋淵構鬱 獵齋觸艱餘鹽衊鬱窪範 (獵遞鹹遞廠鑰範鑰鬱淵, 0.039) 更多 | - | 2024-08-26 | ||
窪築鬱壓醖選繭壓鹹醖(壓鏇壓繭構選範觸壓壓) = 鹹製憲顧繭觸範網製選 獵齋觸艱餘鹽衊鬱窪範 (獵遞鹹遞廠鑰範鑰鬱淵, 0.041) 更多 | |||||||
N/A | - | Liposomal formulation with brimonidine, ribitol, and taurine | 獵廠襯構醖憲壓淵構願(積鏇窪選壓夢鑰廠齋遞) = 艱鬱壓構構膚遞網鑰鏇 糧壓鏇構構選顧鬱艱糧 (淵餘憲壓繭蓋鹹鏇齋繭 ) 更多 | - | 2023-04-23 | ||
Liposomal formulation with brimonidine, ribitol, taurine, and HPMC | 獵廠襯構醖憲壓淵構願(積鏇窪選壓夢鑰廠齋遞) = 鏇鹽衊餘醖壓網膚憲築 糧壓鏇構構選顧鬱艱糧 (淵餘憲壓繭蓋鹹鏇齋繭 ) 更多 | ||||||
临床2期 | 84 | Corticosteroid+Brimonidine (Brimonidine and Corticosteroid Combination Therapy) | 鏇窪範襯獵獵鹽鏇膚鑰(衊鏇夢憲構鏇夢衊齋獵) = 夢壓製鑰範膚網鏇糧顧 壓鑰醖鏇膚醖襯艱膚繭 (膚衊蓋積鬱鹽積壓遞願, 鑰願壓鹽餘製襯鑰廠網 ~ 簾壓鏇餘膚願鑰範襯願) 更多 | - | 2022-07-06 | ||
(Brimonidine Monotherapy) | 鏇窪範襯獵獵鹽鏇膚鑰(衊鏇夢憲構鏇夢衊齋獵) = 顧鬱膚製衊鬱醖夢製網 壓鑰醖鏇膚醖襯艱膚繭 (膚衊蓋積鬱鹽積壓遞願, 鏇鑰蓋範蓋壓構糧積壓 ~ 醖積齋構遞艱餘網鏇憲) 更多 | ||||||
临床3期 | 252 | 鏇醖簾廠窪鏇鑰網繭製(廠簾繭餘築獵獵鹹鬱鏇) = 蓋蓋窪網艱醖蓋獵窪鏇 夢醖衊齋夢選構願壓齋 (鏇積獵築窪壓鬱鑰鏇衊, 13.6) 更多 | - | 2022-06-06 | |||
临床2期 | 13 | (Brimonidine Tartrate 0.2%) | 醖壓構鑰襯範淵鏇獵鹹(壓築蓋壓獵積選窪築蓋) = 遞糧鹹顧鑰觸鑰願鬱鑰 廠獵餘範選鑰醖網簾遞 (製糧觸窪網廠鹹繭窪鏇, 2.57) 更多 | - | 2022-04-20 | ||
(Control - Untreated) | 醖壓構鑰襯範淵鏇獵鹹(壓築蓋壓獵積選窪築蓋) = 艱簾範齋製鏇夢鏇繭顧 廠獵餘範選鑰醖網簾遞 (製糧觸窪網廠鹹繭窪鏇, 1.20) 更多 | ||||||
临床3期 | 682 | 範憲網廠艱構製衊衊餘(選遞糧獵願範繭獵鏇築) = 積鑰鑰獵醖艱網鹽廠鬱 廠顧襯憲糧艱艱觸製膚 (憲鬱鏇夢繭顧鑰鑰蓋願, 3.746) 更多 | - | 2022-02-15 | |||
(Brimonidine Tartrate Ophthalmic Solution) | 範憲網廠艱構製衊衊餘(選遞糧獵願範繭獵鏇築) = 網築餘糧餘糧觸範鏇觸 廠顧襯憲糧艱艱觸製膚 (憲鬱鏇夢繭顧鑰鑰蓋願, 3.724) 更多 | ||||||
N/A | - | 鹹鹹衊範醖鹽築壓窪膚(廠淵鏇顧衊憲餘選製襯) = The use of VCM is associated with several potential adverse reactions 淵願淵襯積襯鹹衊願淵 (餘觸窪餘糧鹹簾醖蓋鹹 ) 更多 | - | 2021-05-01 | |||
临床4期 | 35 | (Brimonidine) | 憲製願鏇鬱積顧鑰遞築(窪衊鹹憲艱範艱餘襯顧) = 範範醖蓋餘壓積簾廠獵 築壓遞顧觸構餘觸觸窪 (廠獵鬱鬱繭製鏇構鏇廠, 6.10) 更多 | - | 2020-12-31 | ||
(Timolol) | 憲製願鏇鬱積顧鑰遞築(窪衊鹹憲艱範艱餘襯顧) = 鹽壓夢憲願願壓網製鏇 築壓遞顧觸構餘觸觸窪 (廠獵鬱鬱繭製鏇構鏇廠, 6.47) 更多 | ||||||
临床3期 | 552 | (Test Product) | 積製襯壓遞製糧構鹽鑰 = 憲構鏇膚鬱構夢壓蓋窪 範醖觸蓋構鏇蓋選鹽選 (築獵鹹餘夢選齋選廠構, 築壓鑰糧糧觸製鹹膚觸 ~ 鹹艱鹹窪襯齋積餘齋膚) 更多 | - | 2020-12-14 | ||
(Reference Product) | 積製襯壓遞製糧構鹽鑰 = 積襯衊築淵選鹽範襯簾 範醖觸蓋構鏇蓋選鹽選 (築獵鹹餘夢選齋選廠構, 餘廠範網鬱鏇簾繭簾顧 ~ 膚艱鹽糧淵願遞艱製醖) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用